Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing ≥ 120 Kilograms versus 60–120 Kilograms

Background Direct oral anticoagulants (DOACs) have become favorable choices for anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non-inferiority or superiority to warfarin. DOACs are currently not recommended in patients with a body weight ≥ 120 kg or body mass inde...

Full description

Saved in:
Bibliographic Details
Published in:American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2021-09, Vol.21 (5), p.545-551
Main Authors: Wiethorn, Eryne E., Bell, Carolyn Magee, Wiggins, Barbara S.
Format: Article
Language:English
Subjects:
Age
Anticoagulants
Body mass index
Cardiac arrhythmia
Cardiology
Clinical trials
Drug dosages
Ethnicity
Heart attacks
Hospitals
Medicine
Medicine & Public Health
Original Research Article
Patients
Pharmacology/Toxicology
Pharmacotherapy
Pulmonary embolisms
Stroke
Thrombosis
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Direct oral anticoagulants (DOACs) have become favorable choices for anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non-inferiority or superiority to warfarin. DOACs are currently not recommended in patients with a body weight ≥ 120 kg or body mass index ≥ 40 kg/m 2 due to limited data regarding safety and efficacy. Objective The aim of this study was to compare the safety and efficacy of DOACs in patients with nonvalvular atrial fibrillation (NVAF) and weighing ≥ 120 kg with those weighing
ISSN:1175-3277
1179-187X
DOI:10.1007/s40256-021-00470-0